期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 6, 期 3, 页码 249-269出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECP.13.18
关键词
antiretroviral therapy; buprenorphine; drug interactions; drug metabolism; hepatitis C; HIV/AIDS; methadone; pharmacodynamics; pharmacokinetic
资金
- National Institute on Drug Abuse [K24 DA017072, R01 DA025932]
- National Institute of Justice
Global access to opioid agonist therapy and HIV/hepatitis C virus (HCV) treatment is expanding but when used concurrently, problematic pharmacokinetic and pharmacodynamic interactions may occur. Articles published from 1966 to 2012 in Medline were reviewed using the following keywords: HIV, AIDS, HIV therapy, HCV, HCV therapy, antiretroviral therapy, highly active antiretroviral therapy, drug interactions, methadone and buprenorphine. In addition, a review of abstracts from national and international meetings and conference proceedings was conducted; selected reports were reviewed as well. The metabolism of both opioid and antiretroviral therapies, description of their known interactions and clinical implications and management of these interactions were reviewed. Important pharmacokinetic and pharmacodynamic drug interactions affecting either methadone or HIV medications have been demonstrated within each class of antiretroviral agents. Drug interactions between methadone, buprenorphine and HIV medications are known and may have important clinical consequences. Clinicians must be alert to these interactions and have a basic knowledge regarding their management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据